產品簡介:
Rapamycin
(Sirolimus) 雷帕霉素(西羅莫司)
產品標簽
Rapamycin 雷帕霉素;Sirolimus 西羅莫司;3-MA
3-甲基腺嘌呤;自吞噬抑制劑 Autophagy inhibitor;mTOR;CAS:53123-88-9;
產品信息
產品名稱
|
產品編號
|
CAS NO.
|
規格
|
價格(元)
|
Rapamycin
(Sirolimus) 雷帕霉素(西羅莫司)
|
MZ0201-10MG
|
53123-88-9
|
10mg
|
248
|
Rapamycin
(Sirolimus) 雷帕霉素(西羅莫司)
|
MZ0201-50MG
|
53123-88-9
|
50mg
|
480
|
Rapamycin
(Sirolimus) 雷帕霉素(西羅莫司)
|
MZ0201-100MG
|
53123-88-9
|
100mg
|
680
|
Rapamycin
(Sirolimus) 雷帕霉素(西羅莫司)
|
MZ0201-500MG
|
53123-88-9
|
500mg
|
2680
|
Rapamycin
(Sirolimus) 雷帕霉素(西羅莫司)
|
MZ0201-1000MG
|
53123-88-9
|
1g
|
3980
|
【溫馨提示】:見我司的小分子化合物常見問題-懋康生物。
產品描述
雷帕霉素(Rapamycin),也稱西羅莫司(Sirolimus),AY 22989,一種分離自細菌的大環內酯化合物,抗真菌劑和免疫抑制劑。雷帕霉素是一種特異性的mTOR抑制劑,IC50為~0.1nM(HEK293細胞)。與細胞內受體FKBP-12結合形成復合物,之后作用于mTOR中的FRB結構域從而抑制蛋白活性。雷帕霉素處理細胞引起p70 S6激酶的去磷酸化和功能失活(IC50= 50 pM)。還能引起4E-BP1/PHAS1去磷酸化,進而促使其結合并失活eIF4E。雷帕霉素能夠阻斷蛋白合成和誘導細胞周期停滯在G1期。還能誘導酵母和哺乳動物細胞的自吞噬現象。能驅使人多能干細胞(hPSC)分化成中內胚層和血液祖細胞。
產品特性
1)CAS NO:53123-88-9
2)化學名:(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,
26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
3)同義名:Sirolimus, Antibiotic AY 22989, AY 22989, Cypher, RAPA, NSC-226080,Rapamune, SILA
9268A
4)分子式:C51H79NO13
5)分子量:914.18
6)純度:≥98%
7)外觀:白色至類白色固體
8)溶解性:溶于DMSO(25mg/ml),乙醇(15mg/ml),幾乎不溶于水
9)化學結構圖:
保存與運輸方法
保存:-20oC干燥保存,至少2年有效。
運輸:室溫運輸。
使用方法【源自文獻,僅作參考】
文獻1,Iwamaru A et al. Silencing mammalian target of rapamycin
signaling by small interfering RNA enhances rapamycin-induced autophagy in
malignant glioma cells. Oncogene. 2007 Mar 22; 26(13):1840-51. PMID: 17001313
體外研究:
細胞類型(Cell type):Human malignant glioma U87-MG and A172 cells
藥物配制(Preparation):Rapamycin was dissolved in DMSO to make 1mM stock solution and
stored at -20℃.
實驗方法(Assay):Tumor cells were exposed to rapamycin (1, 10 or 100 nm) for 24
or 48 h. The cytotoxic effect of rapamycin was determined using a WST-1 cell
proliferation assay.
|
文獻2,Caramés B et al. Autophagy activation by rapamycin reduces
severity of experimental osteoarthritis. Ann Rheum Dis. 2012
Apr;71(4):575-81. PMID: 22084394
體內研究:
動物模型(Animal Model):Experimental osteoarthritis was induced in 2-month-old male
C57Bl/6J mice
藥物配制(Preparation):Rapamycin was dissolved in DMSO at 25mg/ml and stored at -20℃. For injection, the stock solution was diluted in phosphate
buffered saline (PBS).
注射劑量(Dosages):Mice received daily intraperitoneal injections of rapamycin at
1 mg/kg body weight/dose in a total injection volume of 0.3 ml for 10 weeks
and control animals received the DMSO vehicle at 0.4% in a total injection
volume of 0.3 ml.
給藥途徑(Administration):Intraperitoneal (i.p.) injection
|
文獻3,Eshleman JS et al. Inhibition of the Mammalian Target of
Rapamycin Sensitizes U87 Xenografts to Fractionated Radiation Therapy. Cancer
Res. 2002 Dec 15;62(24):7291-7. PMID: 12499272
體外研究:
細胞類型(Cell type):A172, U87, and U118 malignant glioma cell lines
藥物配制(Preparation):Rapamycin (NSC 226080) was dissolved in ethanol to yield a 5
mg/ml stock solution, which was stored at ?20°C.
實驗方法(Assay):Tumor cells were incubated with 0 or 100 nM rapamycin at 37°C for
72 h and then processed in a MTS assay.
體內研究:
動物模型(Animal Model):8-10-week-old female athymic nude mice by s.c. injection of
2-5 million U87 cells
藥物配制(Preparation):For rapamycin injections, stock
rapamycin was diluted first in sterile 10% PEG400/8% ethanol and then in an
equal volume of sterile 10% Tween 80 for a final concentration of 20 μg
rapamycin/100 μl. Rapamycin was delivered by i.p. injection, and the doses of
rapamycin were calculated assuming that all mice weighed 20 g.
給藥途徑(Administration):Intraperitoneal (i.p.) injection
|
注意事項
1)雷帕霉素幾乎不溶于水(文獻報道僅2.6μg/ml)。[Simamora P et al. Int J Pharm. 2001 Feb
1;213(1-2):25-9.]
2)本品不是臨床藥物,只能用于科研用途,不能用于診斷或臨床用途。
3)為了您的安全和健康,請穿實驗服并戴一次性手套操作。
相關產品
— —Written/Edited by V.
Shallan【版權歸MKBio懋康所有】
上海懋康生物科技有限公司是一家涉足于生命科學和生物技術領域研究的試劑、儀器和實驗室消耗品與實驗服務工作,主要從事細胞生物學、植物學、分子生物學、免疫學、生物化學、蛋白組學。生物制藥與診斷試劑研發生產等領域。 本公司秉承“以人為本,以誠為信、合同守信”的經營理念。堅持"品質保障"的原則為廣大客戶提供優質產品。
|